You just read:

MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer

News provided by

MabVax Therapeutics Holdings, Inc.

Feb 23, 2017, 08:30 ET